{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:02:54Z","timestamp":1785790974990,"version":"3.56.0"},"reference-count":103,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Atherosclerosis manifests by the thickening of artery walls and their narrowed channels through the accumulation of plaque. It is one of the most important indicators of cardiovascular disease. It can be caused by various factors, such as smoking, a high cholesterol diet, hypertension, hyperglycemia, and genetic factors. However, atherosclerosis can also develop due to infection. It has been reported that some bacteria and viruses can cause the development of atherosclerosis. Examples of these viruses are influenza viruses, herpes viruses, hepatitis viruses, or papillomaviruses, which are all prevalent and eminent globally for infecting the population worldwide. Moreover, many patients with coronavirus disease 2019 (COVID-19) showed symptoms of cardiovascular disease. In this review paper, the viruses linked to the development of atherosclerosis are introduced, and their viral characteristics, the mechanisms of the development of atherosclerosis, and the current vaccines and antiviral treatment methods are summarized.<\/jats:p>","DOI":"10.3390\/biomedicines10102634","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:32:23Z","timestamp":1666211543000},"page":"2634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Atherosclerosis by Virus Infection\u2014A Short Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-5535","authenticated-orcid":false,"given":"Seang-Hwan","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul 02247, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3141-3727","authenticated-orcid":false,"given":"Kyung-Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul 02247, Korea"},{"name":"Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02247, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of Plaque Formation and Rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week","volume":"72","author":"Libby","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.arcmed.2015.05.006","article-title":"Infection and Atherosclerosis Development","volume":"46","author":"Campbell","year":"2015","journal-title":"Arch. Med Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1093\/eurheartj\/ehx362","article-title":"Infections, atherosclerosis, and coronary heart disease","volume":"38","author":"Pothineni","year":"2017","journal-title":"Eur. Hear. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.120.314513","article-title":"COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients with Cardiovascular Disease","volume":"40","author":"Kadosh","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Vinciguerra, M., Romiti, S., Fattouch, K., Bellis, A.D., and Greco, E. (2020). Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072095"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/qjmed\/hcy305","article-title":"Influenza virus and atherosclerosis","volume":"112","author":"Peretz","year":"2019","journal-title":"QJM"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1093\/cid\/ciq125","article-title":"Pandemic H1N1 Influenza Infection and Vascular Thrombosis","volume":"52","author":"Bunce","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/infdis\/jis597","article-title":"Influenza infection and risk of acute myocardial infarction in England and Wales: A CALIBER self-controlled case series study","volume":"206","author":"Hayward","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00705-016-3093-3","article-title":"IL-1\u03b2 is a key cytokine that induces trypsin upregulation in the influenza virus-cytokine-trypsin cycle","volume":"162","author":"Indalao","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0264-410X(00)00275-9","article-title":"Inflammatory responses in influenza A virus infection","volume":"19","author":"Julkunen","year":"2000","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajpath.2011.03.013","article-title":"Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis","volume":"179","author":"Narasaraju","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/JVI.06348-11","article-title":"Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: Possible involvement in the pathogenesis of human H5N1 virus infection","volume":"86","author":"Zeng","year":"2012","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1086\/656044","article-title":"Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza","volume":"202","author":"Wang","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14264","DOI":"10.1038\/s41598-020-70753-0","article-title":"Modelling the linkage between influenza infection and cardiovascular events via thrombosis","volume":"10","author":"McCarthy","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection","volume":"378","author":"Kwong","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e018756","DOI":"10.1161\/JAHA.120.018756","article-title":"Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages","volume":"10","author":"Demina","year":"2021","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mezentsev, A., Bezsonov, E., Kashirskikh, D., Baig, M.S., Eid, A.H., and Orekhov, A. (2021). Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060600"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJMoa025028","article-title":"Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly","volume":"348","author":"Nichol","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1161\/01.CIR.102.25.3039","article-title":"Association of influenza vaccination and reduced risk of recurrent myocardial infarction","volume":"102","author":"Naghavi","year":"2000","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104502","DOI":"10.1016\/j.meegid.2020.104502","article-title":"From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses","volume":"85","author":"Kirtipal","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.abm4454","article-title":"Dissecting the early COVID-19 cases in Wuhan","volume":"374","author":"Worobey","year":"2021","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Poznyak, A.V., Bezsonov, E.E., Eid, A.H., Popkova, T.V., Nedosugova, L.V., Starodubova, A.V., and Orekhov, A.N. (2021). ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094691"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a target in COVID-19?","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMc2009020","article-title":"ST-Segment Elevation in Patients with COVID-19\u2013A Case Series","volume":"382","author":"Bangalore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0140-6736(20)30912-0","article-title":"Myocarditis in a patient with COVID-19: A cause of raised troponin and ECG changes","volume":"395","author":"Doyen","year":"2020","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"COVID-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_33","unstructured":"The National Institutes of Health (2022, August 24). Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/summary-recommendations\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.JAA.0000586300.88300.84","article-title":"A clinical review of viral hepatitis","volume":"32","author":"Loader","year":"2019","journal-title":"JAAPA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3748\/wjg.v27.i16.1691","article-title":"From hepatitis A to E: A critical review of viral hepatitis","volume":"27","author":"Castaneda","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1086\/317613","article-title":"The possible role of hepatitis A virus in the pathogenesis of atherosclerosis","volume":"182","author":"Zhu","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/STROKEAHA.106.466268","article-title":"Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction","volume":"38","author":"Sung","year":"2007","journal-title":"Stroke"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","article-title":"Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis","volume":"221","author":"Adinolfi","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","article-title":"Effects of hepatitis C virus on cardiovascular risk in infected patients: A comparative study","volume":"164","author":"Oliveira","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.amjcard.2014.09.020","article-title":"Impact of hepatitis C seropositivity on the risk of coronary heart disease events","volume":"114","author":"Pothineni","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Migueres, M., Lhomme, S., and Izopet, J. (2021). Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses, 13.","DOI":"10.3390\/v13101900"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coviro.2021.10.002","article-title":"Immunotherapy and therapeutic vaccines for chronic HBV infection","volume":"51","author":"Thimme","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., May, M.T., Turner, K.M., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140765"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., Turner, K.M., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128615"},{"key":"ref_45","first-page":"351","article-title":"Herpes simplex virus as a determinant risk factor for coronary artery atherosclerosis and myocardial infarction","volume":"19","author":"Kotronias","year":"2005","journal-title":"Vivo"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcv.2004.06.010","article-title":"Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts","volume":"32","author":"Ibrahim","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_47","first-page":"2630865","article-title":"Herpes Simplex Virus Type 1 and Type 2 Infection Increases Atherosclerosis Risk: Evidence Based on a Meta-Analysis","volume":"2016","author":"Wu","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1440-1827.2002.01312.x","article-title":"Herpesvirus (HSV-1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue","volume":"52","author":"Shi","year":"2002","journal-title":"Pathol. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/0882824041310531","article-title":"Herpes simplex virus 1 induced LOX-1 expression in an endothelial cell line, ECV 304","volume":"17","author":"Chirathaworn","year":"2004","journal-title":"Viral Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI113208","article-title":"Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis","volume":"80","author":"Hajjar","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13510","DOI":"10.1073\/pnas.94.25.13510","article-title":"Coagulation initiated on herpesviruses","volume":"94","author":"Sutherland","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2012.03.002","article-title":"Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: Multicenter AIDS cohort study","volume":"223","author":"Hechter","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Stanfield, B.A., Kousoulas, K.G., Fernandez, A., and Gershburg, E. (2021). Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses, 13.","DOI":"10.3390\/v13081637"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sadowski, L.A., Upadhyay, R., Greeley, Z.W., and Margulies, B.J. (2021). Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2. Viruses, 13.","DOI":"10.3390\/v13071228"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2013.06.007","article-title":"Diseases associated with human papillomavirus infection","volume":"445","author":"Cubie","year":"2013","journal-title":"Virology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study","volume":"11","author":"Quint","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","article-title":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial","volume":"137","author":"Monsonego","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcvm.2015.00017","article-title":"Identification of Human Papilloma Viruses in Atheromatous Coronary Artery Disease","volume":"2","author":"Lawson","year":"2015","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.jacc.2011.07.038","article-title":"Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006","volume":"58","author":"Kuo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4103\/0973-029X.190896","article-title":"To analyze the concomitant expression of human papillomavirus-16 in the pathogenetic model of p53-dependant pathway in oral squamous cell carcinoma","volume":"20","author":"Rathore","year":"2016","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/01.ATV.19.3.575","article-title":"Generation and characterization of human smooth muscle cell lines derived from atherosclerotic plaque","volume":"19","author":"Bonin","year":"1999","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/6585","article-title":"The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo","volume":"5","author":"Guevara","year":"1999","journal-title":"Nat. Med."},{"key":"ref_63","first-page":"101","article-title":"Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil","volume":"10","author":"Soliman","year":"2021","journal-title":"Int. J. Mol. Cell. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e20341","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcimb.2020.00130","article-title":"Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response","volume":"10","author":"Forte","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Poole, E., and Sinclair, J. (2020). Understanding HCMV Latency Using Unbiased Proteomic Analyses. Pathogens, 9.","DOI":"10.3390\/pathogens9070590"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.20411\/pai.v5i1.382","article-title":"Novel Strategies to Combat CMV-Related Cardiovascular Disease","volume":"5","author":"Vasilieva","year":"2020","journal-title":"Pathog. Immun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1386-6532(99)00064-5","article-title":"The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis","volume":"16","year":"2000","journal-title":"J. Clin. Virol."},{"key":"ref_71","first-page":"23","article-title":"High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis","volume":"136","author":"Hendrix","year":"1990","journal-title":"Am. J. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2004.07.010","article-title":"Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36","volume":"177","author":"Carlquist","year":"2004","journal-title":"Atherosclerosis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0092-8674(00)81539-1","article-title":"The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration","volume":"99","author":"Streblow","year":"1999","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/01.CIR.99.13.1656","article-title":"Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells","volume":"99","author":"Tanaka","year":"1999","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/S0140-6736(03)15016-7","article-title":"Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis","volume":"362","author":"Bason","year":"2003","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.7150\/thno.27428","article-title":"CD28null pro-atherogenic CD4 T-cells explain the link between CMV infection and an increased risk of cardiovascular death","volume":"8","author":"Pera","year":"2018","journal-title":"Theranostics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/317938","article-title":"Atherosclerosis in apoE knockout mice infected with multiple pathogens","volume":"183","author":"Burnett","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12265-012-9428-x","article-title":"Murine cytomegalovirus (MCMV) infection upregulates P38 MAP kinase in aortas of Apo E KO mice: A molecular mechanism for MCMV-induced acceleration of atherosclerosis","volume":"6","author":"Lochhead","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.micinf.2003.09.024","article-title":"Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation","volume":"6","author":"Vliegen","year":"2004","journal-title":"Microbes Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2004.12.035","article-title":"Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic mice","volume":"181","author":"Vliegen","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Perera, M.R., Wills, M.R., and Sinclair, J.H. (2021). HCMV Antivirals and Strategies to Target the Latent Reservoir. Viruses, 13.","DOI":"10.3390\/v13050817"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/590150","article-title":"Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions","volume":"47","author":"Effros","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1464-2662.2001.00096.x","article-title":"Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART","volume":"3","author":"Stone","year":"2002","journal-title":"HIV Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V97.2.352","article-title":"HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes","volume":"97","author":"Park","year":"2001","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/ATVBAHA.113.302191","article-title":"HIV, inflammation, and calcium in atherosclerosis","volume":"34","author":"Shrestha","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"H1336","DOI":"10.1152\/ajpheart.01095.2008","article-title":"Microarray analysis of gene expression in mouse aorta reveals role of the calcium signaling pathway in control of atherosclerosis susceptibility","volume":"296","author":"Yuan","year":"2009","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1089\/ars.2007.1780","article-title":"Role of endoplasmic reticulum calcium disequilibria in the mechanism of homocysteine-induced ER stress","volume":"9","author":"Dickhout","year":"2007","journal-title":"Antioxidants Redox Signal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/CIRCRESAHA.110.224766","article-title":"The role of endoplasmic reticulum stress in the progression of atherosclerosis","volume":"107","author":"Tabas","year":"2010","journal-title":"Circ. Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, W.M., Lundgren, J., Neaton, J.D., Gordin, F., Abrams, D., Arduino, R.C., Babiker, A., Burman, W., and Clumeck, N. (2006). CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med., 355, 2283\u20132296.","DOI":"10.1056\/NEJMoa062360"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"SMART Study Group, El-Sadr, W.M., Grund, B., Neuhaus, J., Babiker, A., Cohen, C.J., Darbyshire, J., Emery, S., Lundgren, J.D., and Phillips, A. (2008). Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial. Ann. Intern. Med., 149, 289\u2013299.","DOI":"10.7326\/0003-4819-149-5-200809020-00003"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Cunha, R.F., Sim\u00f5es, S., Carvalheiro, M., Pereira, J.M.A., Costa, Q., and Ascenso, A. (2021). Novel Antiretroviral Therapeutic Strategies for HIV. Molecules, 26.","DOI":"10.3390\/molecules26175305"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: Long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_94","unstructured":"The Centers for Disease Control and Prevention (2022, August 24). Preexposure Prophylaxis for the Prevention of HIV Infection in The United States\u20132021 Update, Available online: https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf."},{"key":"ref_95","unstructured":"The Centers for Disease Control and Prevention (2022, August 24). HIV\u2013Pre-Exposure Prophyljaxis (PrEP), Available online: https:\/\/www.cdc.gov\/hiv\/clinicians\/prevention\/prep.html."},{"key":"ref_96","unstructured":"The United States Food and Drug Administration (2022, August 24). FDA NEWS RELEASE\u2013FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Poznyak, A.V., Bezsonov, E.E., Borisov, E.E., Grechko, A.V., Kartuesov, A.G., and Orekhov, A.N. (2022). Atherosclerosis in HIV Patients: What Do We Know so Far?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052504"},{"key":"ref_98","first-page":"410","article-title":"HIV, Combination Antiretroviral Therapy, and Vascular Diseases in Men and Women","volume":"7","author":"Kovacs","year":"2022","journal-title":"JACC: Basic Transl. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s10096-018-3370-z","article-title":"Viral infection and atherosclerosis","volume":"37","author":"Hemmat","year":"2018","journal-title":"Eur. J. Clin. Microbiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1160\/TH11-06-0392","article-title":"Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis","volume":"106","author":"Rosenfeld","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Magadum, A., and Kishore, R. (2020). Cardiovascular Manifestations of COVID-19 Infection. Cells, 9.","DOI":"10.3390\/cells9112508"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Maitz, T., Parfianowicz, D., Vojtek, A., Rajeswaran, Y., Vyas, A.V., and Gupta, R. (2022). COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities. Curr. Probl. Cardiol., 101186.","DOI":"10.1016\/j.cpcardiol.2022.101186"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/2470-7511.334401","article-title":"COVID-19-induced cardiovascular damage differs from other prevalent viruses","volume":"6","author":"Parise","year":"2021","journal-title":"Cardiol. Plus"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:26Z","timestamp":1760144246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":103,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102634"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102634","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}